Ultra-sensitive immunoassays are those reaching limits of detection below those of standard immunoassays.
But this increased sensitivity comes at a cost: in money, time, training, or specific drawbacks that depend on how an assay reaches ultra-sensitivity, so using ultra-sensitive immunoassays for every application is not ideal.
Still, there are multiple research areas where the benefit is significant, with ultra-sensitivity providing additional data and knowledge that makes the investment worthwhile. For example, increased sensitivity is helping researchers better understand how disease works, discover correlations with predictive potential, and create a knowledge base from which new diagnostic and therapeutic approaches can be developed.
If you want to know about the latest research advances happening thanks to ultra-sensitive immunoassays and how you too could use them in your research, keep reading. We will cover some great research published over the last 3 years using ultra-sensitive immunoassays.
Summary:
- Ultra-sensitive immunoassays let researchers detect analytes at lower concentrations than standard immunoassays, providing more accurate quantification and dynamic ranges that can span analyte concentrations in healthy and diseased subjects.
- The latest research covers neurodegeneration (Alzheimer’s disease and multiple sclerosis), immune response and infections (cytokine measurements in cell models, multiplex cytokine panels, HIV, and neonatal sepsis), and injury and cancer biomarkers.
- The breakthroughs achieved thanks to ultra-sensitive immunoassays provide a better understanding of disease and the foundations for future diagnostic tests, accurate disease prediction and monitoring, and personalized care.
- BOLD, Cavidi’s signal amplification system, can be added to your immunoassays to make them ultra-sensitive, with proven results detecting key proteins in many research areas, including Alzheimer’s, cytokine detection, and myocardial injury biomarkers.
When do ultra-sensitive immunoassays actually pay off?
Regardless of research area, there are three common situations where scientists choose to invest in ultra-sensitive immunoassays. These are when:
- The analyte falls below a standard immunoassay’s limit of detection (LoD).
- The analyte falls below the lower limit of quantification (LLOQ).
- The dynamic range does not cover low enough analyte concentrations.
If one of these situations accurately describes your current assay, consider going ultra-sensitive. If you are unsure, use our pre-upgrade checklist to see whether turning ultra-sensitive is the right choice for you.
A pre-upgrade checklist (before turning to ultra-sensitive immunoassays)

When transitioning to an ultra-sensitive immunoassay, choose the lowest-complexity route: signal amplification add-ons (like Exazym® and BOLD) allow you to keep your workflow and instruments. New dedicated platforms require new instruments, higher investment, and often, changing your assay.
If you want to know more about ultra-sensitive immunoassays in general, what types there are, and how they work, check our previous article on the origins, methods, and applications of ultra-sensitive immunoassays.
Research areas benefiting from ultra-sensitive immunoassays
Ultra-sensitive immunoassays are most promising in areas where detecting very low concentrations of biomarkers can improve our understanding of disease or open up new diagnostic and therapeutic possibilities. They are also useful when sample volumes are limited. Below are some of the areas where these assays are making a difference, along with recent findings.
Neurodegeneration & CNS biomarkers from blood
Neurodegeneration biomarkers in blood, plasma, or serum are present at very low concentrations, as proteins related to these conditions reach the bloodstream in small numbers. As a result, the quantity of biomarkers before severe symptom onset or in healthy individuals often lies below most immunoassays’ sensitivity. The detection and quantification of these low-abundance biomarkers is now possible thanks to ultra-sensitive immunoassays, opening the door to developing predictive models, understanding disease progression, developing less invasive tests, and monitoring treatment.

Alzheimer’s disease
Tau protein phosphorylated at residue 217 (p-tau217) is a biomarker of Alzheimer’s disease (AD) in plasma. In 2026, researchers published a model able to predict the onset of AD symptoms based on the levels of p-tau217 in plasma, based on the analysis of plasma from hundreds of people1. For this analysis, they used both liquid chromatography-mass spectrometry and ultra-sensitive immunoassays, as the levels of p-tau217 fall below conventional immunoassay limits. Current AD prediction models usually rely on PET scans, making them expensive and difficult to scale.
While these results are only a first step, in the future, a simple blood sample could be enough to predict how long it will take for someone to develop AD symptoms, something that could be of use in clinical trials, diagnostics, and more.
But that’s not all. Researchers also know that not every AD case evolves in the same way, with some patients developing symptoms faster than others.
A new study found that plasma p-tau217 levels and its changes over time were associated with how quickly cognition declined in amyloid-positive AD participants2. The study describes different subsets of patients that differ in the speed of severe AD symptom onset.
Identifying these subgroups can help researchers understand why AD does not progress equally in everyone, and eventually lead to more personalized treatment approaches led by biomarker-based predictions.
Multiple sclerosis
The use of neurodegeneration biomarkers to monitor disease progression extends beyond AD.
Recently, scientists published new data linking serum neurofilament light chain (sNfL) concentration with the impact of multiple sclerosis in the brain3. They used ultra-sensitive immunoassays to detect sNfL, and found that its concentration in blood correlated with lower gray matter in multiple sclerosis patients. While sNfL had been detected before in blood, these new findings provide researchers with a way to correlate a blood biomarker to changes in the brain linked to disease. In the future, this could help make disease monitoring easier and less invasive.
Immune and infectious activity
Many immune proteins and pathogens are present at extremely low levels in blood during the early stages of disease. But it’s precisely at those stages that early treatment can make the largest impact. Understanding shifts in signaling immune molecules can also help us better understand the role and activation patterns of immune cells, advancing immune therapies, biomanufacturing, and more.

Cytokines
When it comes to immune activity, cytokines are scarce in blood even when the immune system is active, and more so at resting states. Ultra-sensitive immunoassays are very useful to detect and quantify them accurately, and to match immune cell activity with the presence of cytokines in blood.
When cell cultures or small animals are used in research, the issue is even more severe due to low sample volume. While exploring nanomedicine approaches to treat cancer, a research team ended up putting together an ultra-sensitive immunoassay workflow to measure secreted cytokines in cell culture media4. This allowed them to overcome the high number of cells needed when working with other methods like mass spectrometry.
Using the developed ultra-sensitive immunoassay, researchers measured secreted IL-6 under different treatment conditions and separately demonstrated Ras detection in tumor-cell lysates. This could empower researchers to perform experiments faster and more accurately, replacing animals with cell cultures, and reducing the quantity of cells needed.
Another group of scientists created a multiplex ultra-sensitive immunoassay to measure IL-4, IL-5, IL-6, IL-9, and IL-17 in blood samples in one go, achieving an LoD in the fg/mL range5. The assay works for human serum and could be used for research, clinical trials, and diagnostics in the future.
Infectious disease monitoring
Ultra-sensitive immunoassays are also relevant for HIV monitoring. People with HIV undergoing antiretroviral therapy can still show persistent activation of the immune system, the cause of which has been unclear until recently.
Scientists were able to measure p24, an HIV-1 protein, in the blood of people with chronic HIV, using ultra-sensitive immunoassays. The results showed that the immune system activation could be caused by ongoing p24 production and viral activity despite treatment6. This breakthrough gives us a better understanding of the virus and disease, and could lead to improved treatments.
Ultra-sensitive immunoassays could also be used to speed up less invasive diagnostics in infants. Neonatal infection and sepsis are leading causes of death in babies, but to test the state of the disease, blood must be drawn, and results can take up to 5 days.
Researchers have now detected relevant immune proteins in infant saliva (CXCL6, CCL20) using ultra-sensitive immunoassays7. They reported that levels of these proteins correlate with infection, making the findings a start for faster, non-invasive diagnostic tests in the future.
Injury and cancer biomarkers
Cancer, infarct, liver failure, and other life-threatening conditions don’t set in immediately. Rather, they develop progressively. Biomarkers are used to detect these conditions before they become deadly, and ultra-sensitivity allows us to do so even when biomarker concentration is very low. These advances provide more information about disease onset so we can understand, predict, and treat these conditions earlier, increasing the chances of positive outcomes for patients.

Heart injury
Cardiac troponin I (cTnI) is a classic biomarker of myocardial injury, present in cases of infarction. It’s because of this that several high-sensitivity cTnI tests have received 510(k) clearance from the FDA. High-sensitivity cTnI assays are expected to measure the analyte above the detection limit in more than 50% of healthy women and men (with median population values at 3 pg/mL), with ≤10% imprecision at the assay-specific 99th-percentile upper reference limit8.
Ultra-sensitive immunoassays for cTnI are constantly being developed to push these detection limits further and improve the early detection of infarction and myocardial damage. A recent paper describes a dynamic range of 0.1-5,000 pg/mL for an ultra-sensitive immunoassay against cTnI9.
Cancer detection
Beyond cardiovascular and neurodegenerative diseases, ultra-sensitive immunoassays are also being explored for cancer biomarker detection.
An example is a transposon protein called LINE-1 ORF1p, which is often expressed in many types of cancers. A team of scientists managed to develop and improve an ultra-sensitive immunoassay to detect this protein in the blood of patients with gastroesophageal, colon, and ovarian cancer10. LINE-1 ORF1p was not detectable at baseline levels and in some cancer samples using commercially available ultra-sensitive platforms. The improved ultra-sensitive immunoassay let scientists detect and quantify the protein more accurately, and in more samples. New ultra-sensitive advances can increase accuracy and quantification between samples, for many applications. Regarding cancer specifically, the concentration of LINE-1 ORF1p in blood was associated with overall survival in some of the cancer types that were studied.
Use BOLD to add ultra-sensitivity to your immunoassay
The breakthroughs happening thanks to ultra-sensitive immunoassays are just beginning. As we discover more low-quantity biomarkers and ultra-sensitive approaches become easier, more flexible, and cheaper, ultra-sensitive immunoassays will only gain traction.
And our kits allow any user to make their immunoassay ultra-sensitive. Thanks to our signal amplification technology, BOLD, you can turn your ELISA, suspension bead array (SBA) like Luminex, or other automated immunoassays ultra-sensitive.
In fact, BOLD has been successfully used to ultra-sensitively detect many of the analytes described above. This includes:
- A 60x lower LoD on an ELISA using BOLD when detecting pTau181, another AD biomarker.
- 6x lower LoD when detecting TNF-α, 11x when detecting IL-23, and nearly 50x when detecting IL-4.
- A 67x lower LoD with BOLD on an ELISA when detecting SARS-CoV-2 spike protein11.
- A 180x lower LoD with BOLD than with traditional ELISA when detecting cTnI.
So, if you want to increase your immunoassay’s sensitivity, signal amplification add-ons like BOLD are the easiest way to do so. Check our products or get in touch and we’ll make sure an expert helps you.
Frequently Asked Questions (FAQs)
1. When is an ultra-sensitive immunoassay worth using?
When your current assay’s LoD, LLOQ, or dynamic range doesn’t cover the analyte concentration in the samples you have. When that’s the case, look for ultra-sensitive immunoassay alternatives. Some of them, like BOLD, provide additional signal amplification and let you keep your immunoassay’s antibodies, reader, and workflow. Others require expensive and dedicated instruments and changing your reagents and workflow.
2. Which research areas benefit most from ultra-sensitive detection?
Research on low-abundance biomarkers is an area that thrives particularly thanks to ultra-sensitive immunoassays. This includes blood-based neurodegeneration markers, cytokines (especially in small-volume samples), viral proteins, and emerging injury or cancer biomarkers. In many of these cases, the improved sensitivity allows researchers to measure samples that previously fell below the assay’s quantifiable range, providing new data that can lead to new insights, understanding, and discoveries.
3. Do I need a new instrument to make my ELISA more sensitive?
No. Dedicated platforms are one option, but signal amplification can be added to an existing immunoassay workflow. Cavidi’s BOLD technology, commercially available through Exazym® kits, lets you keep your workflow, antibodies, and detector system rather than requiring new dedicated equipment. BOLD has been used to increase the sensitivity of existing immunoassays, lowering their LoD 6–180x in the examples above. BOLD typically provides 10–100x signal amplification.
References
- Petersen, K.K., Milà-Alomà, M., et al. Predicting Onset of Symptomatic Alzheimer’s Disease with Plasma p-tau217 Clocks. 2026. Nature Medicine, 32(3), 1085–1094. https://doi.org/10.1038/s41591-026-04206-y
- Kirsebom, B.-E., Gonzalez-Ortiz, F., et al. Repeated Plasma p-tau217 Measurements to Monitor Clinical Progression Heterogeneity. 2025. Alzheimer’s & Dementia, 21(5), e70319. https://doi.org/10.1002/alz.70319
- Ciubotaru, A., Covali, R., et al. Integrated Biomarker–Volumetric Profiling Defines Neurodegenerative Subtypes and Predicts Neuroaxonal Injury in Multiple Sclerosis Based on Bayesian and Machine Learning Analyses. 2026. Biomedicines, 14(1), 42. https://doi.org/10.3390/biomedicines14010042
- Cheng, C.-A., Chiang, L.-C., et al. Integrated Pipeline for Ultrasensitive Protein Detection in Cancer Nanomedicine. 2023. RSC Advances, 13(21), 14685–14697. https://doi.org/10.1039/d3ra02092d
- Choi, J.H., Kim, Y.H., et al. Tyramide Signal Amplification for a Highly Sensitive Multiplex Immunoassay Based on Encoded Hydrogel Microparticles. 2025. Analyst, 150(10), 2118–2127. https://doi.org/10.1039/d5an00078e
- Richter, E., König, J., et al. Ultra-Low Level HIV p24 Drives Immune Activation in Antiretroviral Therapy-Treated People Living with HIV. 2025. Communications Medicine, 5, 510. https://doi.org/10.1038/s43856-025-01261-3
- Bellon Pizarro, K.N., Rolando, J.C., et al. Ultrasensitive Detection of Six Sepsis-Associated Proteins in Neonatal Saliva. 2025. npj Biosensing, 2, 3. https://doi.org/10.1038/s44328-025-00026-1
- McKie, P.M., Heublein, D.M., et al. Defining High-Sensitivity Cardiac Troponin Concentrations in the Community. 2013. Clinical Chemistry, 59(7), 1099–1107. https://doi.org/10.1373/clinchem.2012.198614
- Lou, F., Zhang, H., et al. Liposome-Embedded PtCu Nanozymes for Improved Immunoassay of Accurate Myocardial Infarction. 2024. Talanta, 279, 126576. https://doi.org/10.1016/j.talanta.2024.126576
- Taylor, M.S., Wu, C., et al. Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker. 2023. Cancer Discovery, 13(12), 2532–2547. https://doi.org/10.1158/2159-8290.CD-23-0313
- Nordal, V., Hedin, J., et al. Reverse Transcriptase Mediated Signal Amplification in Ligand Binding Assays. 2026. SLAS Technology, 39, 100423. https://doi.org/10.1016/j.slast.2026.100423
